Substance abuse disorder that involves the recurring use of opioid drugs despite negative consequences.
1
Findings fit negative reinforcement models associated with risk of developing opioid use disorder.
2
It also reviews the neurocognitive impact of pharmaceutical treatments for opioid use disorder.
3
Over this same period, monthly opioid use disorder diagnoses nearly tripled.
4
In women with opioid use disorder prenatal UDT results alone are insufficient to guide breastfeeding decisions.
5
During that period, 4,837 young people were diagnosed with opioid use disorder.
6
More research is needed to understand how these factors could improve treatment outcomes for those with opioid use disorder.
7
Conclusions: XR-NTX treatment in smokers with opioid use disorder was associated with a 29% decline in daily cigarette consumption.
8
Their analysis focused on patients receiving prescriptions for buprenorphine, one of three drugs typically used to treat patients with opioid use disorder.
9
We hypothesized that treatment with XR-NTX for would lead to a reduction in smoking in tobacco cigarette smokers with opioid use disorder.
10
Cannabis use in some individuals can meaningfully introduce de novo risk for the initiation of opioid use and development of opioid use disorder.
11
This disparity raises the question of whether opioids facilitate smoking among individuals with opioid use disorder and whether opioid antagonists may reduce it.
12
During the study, the proportion of people diagnosed with opioid use disorder who filled prescriptions for buprenorphine climbed from about one-third to three-fourths.
13
Individuals who receive buprenorphine treatment for opioid use disorder in office-based settings may be at risk for, or have a history of, polysubstance use.
14
The MOR-Gal1R heteromer can explain previous results showing antagonistic galanin- opioid interactions and offers a new therapeutic target for the treatment of opioid use disorder.
15
Methods: Retrospective cohort study of pregnant women with opioid use disorder on methadone or buprenorphine between 2006 and 2015.
16
The researchers also estimate that about 1 percent of adults, or about 1.9 million Americans, had an opioid use disorder.